CHEREE' BODDEN: Open Payments
NPI 1790261618 · BATON ROUGE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$268 in 12 payments from 9 companies in 2025. Trend: 2023 $453 · 2024 $132 · 2025 $268
Food & beverage: $268
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 4 | $98 |
| SOBI, INC | 1 | $28 |
| GENZYME CORPORATION | 1 | $27 |
| Daiichi Sankyo Inc. | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $20 |
| Gilead Sciences, Inc. | 1 | $18 |
| ABBVIE INC. | 1 | $18 |
| E.R. Squibb & Sons, L.L.C. | 1 | $17 |
| TerSera Therapeutics LLC | 1 | $15 |
Products named: SCEMBLIX, Fabhalta, Doptelet, SARCLISA, INJECTAFER, DANZITEN, Trodelvy, EPKINLY.
Industry payments across LA — which companies pay providers there.
